Pfizer (PFE, $42.21) vaccine gets FDA optimism before emergency approval meeting
Pfizer and BioNTech's jointly developed coronavirus vaccine could be effective after just one dose, the U.S. Food & Drug Administration said Tuesday in its first report. The report comes ahead of its Thursday assessment of the Emergency Use Authorization (EUA) request filed by Pfizer last month.
According to the FDA, individuals infected with COVID 19 could benefit from the Pfizer vaccine. The FDA noted that the vaccine's efficacy after one dose, but before the second dose, was around 52%; its efficacy for trial participants over the age of 55 was 94% after both doses. .It has not noted any specific concerns from the late-stage trials.
Last month, Pfizer said that the vaccine, called BNT162b2, had a 95% efficacy rate across all age and race demographics. The pharmaceutical company said it would be ready to distribute the vaccine 'within hours' of approval by the FDA.
The Centers for Disease Control would take the final decision on allocation at the state and national level.
PFE in downward trend: price may decline as a result of having broken its higher Bollinger Band on February 10, 2026
PFE broke above its upper Bollinger Band on February 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 46 similar instances where the stock broke above the upper band. In of the 46 cases the stock fell afterwards. This puts the odds of success at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on March 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PFE as a result. In of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for PFE turned negative on February 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 58 cases where PFE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in of 290 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 204 cases where PFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Valuation Rating for company is (best 1 - 100 worst), which means the company is slightly undervalued. The valuation of the company is based on a proprietary formula which takes into account a set of fundamentals and gives us an estimate of the price per share for the company. We then compare this estimate with the current price per share. As a result, this company is rated as undervalued in the industry. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.748) is normal, around the industry mean (9.237). P/E Ratio (19.544) is within average values for comparable stocks, (22.032). PFE's Projected Growth (PEG Ratio) (13.773) is very high in comparison to the industry average of (2.438). PFE's Dividend Yield (0.065) is considerably higher than the industry average of (0.026). P/S Ratio (2.427) is also within normal values, averaging (3.842).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of vaccines and injectable biologic medicines
Industry PharmaceuticalsMajor
Advertisement